136 related articles for article (PubMed ID: 26917670)
1. Two Unique Glioma Subtypes Revealed.
Poh A
Cancer Discov; 2016 Apr; 6(4):334-5. PubMed ID: 26917670
[TBL] [Abstract][Full Text] [Related]
2. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
3. Confirmation of R132H mutation of isocitrate dehydrogenase 1 as an independent prognostic factor in anaplastic astrocytoma.
Schittenhelm J; Mittelbronn M; Meyermann R; Melms A; Tatagiba M; Capper D
Acta Neuropathol; 2011 Nov; 122(5):651-2. PubMed ID: 21983902
[No Abstract] [Full Text] [Related]
4. [IDH mutation on glioma].
Mukasa A
Gan To Kagaku Ryoho; 2011 Jun; 38(6):937-40. PubMed ID: 21751529
[No Abstract] [Full Text] [Related]
5. Molecular subtypes of glioma identified by genome-wide methylation profiling.
Kloosterhof NK; de Rooi JJ; Kros M; Eilers PH; Sillevis Smitt PA; van den Bent MJ; French PJ
Genes Chromosomes Cancer; 2013 Jul; 52(7):665-74. PubMed ID: 23629961
[TBL] [Abstract][Full Text] [Related]
6. cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant.
Louis DN; Giannini C; Capper D; Paulus W; Figarella-Branger D; Lopes MB; Batchelor TT; Cairncross JG; van den Bent M; Wick W; Wesseling P
Acta Neuropathol; 2018 Apr; 135(4):639-642. PubMed ID: 29497819
[No Abstract] [Full Text] [Related]
7. Tailored therapy in diffuse gliomas: using molecular classifiers to optimize clinical management.
Taylor JW; Chi AS; Cahill DP
Oncology (Williston Park); 2013 Jun; 27(6):504-14. PubMed ID: 23909061
[TBL] [Abstract][Full Text] [Related]
8. Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma.
Gravendeel LA; Kloosterhof NK; Bralten LB; van Marion R; Dubbink HJ; Dinjens W; Bleeker FE; Hoogenraad CC; Michiels E; Kros JM; van den Bent M; Smitt PA; French PJ
Hum Mutat; 2010 Mar; 31(3):E1186-99. PubMed ID: 20077503
[TBL] [Abstract][Full Text] [Related]
9. Glioma-derived mutations in IDH: from mechanism to potential therapy.
Fu Y; Huang R; Du J; Yang R; An N; Liang A
Biochem Biophys Res Commun; 2010 Jun; 397(2):127-30. PubMed ID: 20510884
[TBL] [Abstract][Full Text] [Related]
10. BRAF V600E-mutated diffuse glioma in an adult patient: a case report and review.
Suzuki Y; Takahashi-Fujigasaki J; Akasaki Y; Matsushima S; Mori R; Karagiozov K; Joki T; Ikeuchi S; Ikegami M; Manome Y; Murayama Y
Brain Tumor Pathol; 2016 Jan; 33(1):40-9. PubMed ID: 26445861
[TBL] [Abstract][Full Text] [Related]
11. Re-evaluation of nondiagnostic biopsies of suspected low-grade glioma using isocitrate dehydrogenase 1 mutation immunohistochemistry.
Anderson MD; Abel TW; Moots PL
Neuro Oncol; 2013 Jul; 15(7):811-3. PubMed ID: 23737489
[No Abstract] [Full Text] [Related]
12. [Mutations of IDH1 and 2 genes: a molecular diagnosis of low-grade gliomas].
Larsen CJ
Bull Cancer; 2009 Jun; 96(6):641-2. PubMed ID: 19585679
[No Abstract] [Full Text] [Related]
13. Correspondence regarding: diagnostic utility of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed paraffin-embedded glioma tissues. J Neuropathol Exp Neurol 2009:68;1319-25.
Wiwanitkit V
J Neuropathol Exp Neurol; 2010 Mar; 69(3):320; author reply 320-1. PubMed ID: 20190607
[No Abstract] [Full Text] [Related]
14. Magnetic resonance metabolic imaging of glioma.
Metellus P; Figarella-Branger D
Sci Transl Med; 2012 Jan; 4(116):116ps1. PubMed ID: 22238331
[TBL] [Abstract][Full Text] [Related]
15. Recognition of Tumor-Associated Antigens and Immune Subtypes in Glioma for mRNA Vaccine Development.
Ma S; Ba Y; Ji H; Wang F; Du J; Hu S
Front Immunol; 2021; 12():738435. PubMed ID: 34603319
[TBL] [Abstract][Full Text] [Related]
16. Glioma IDH1 mutation patterns off the beaten track.
Pusch S; Sahm F; Meyer J; Mittelbronn M; Hartmann C; von Deimling A
Neuropathol Appl Neurobiol; 2011 Jun; 37(4):428-30. PubMed ID: 20874727
[No Abstract] [Full Text] [Related]
17. On high-risk, low-grade glioma: What distinguishes high from low?
Geurts M; van den Bent MJ
Cancer; 2019 Jan; 125(2):174-176. PubMed ID: 30512190
[TBL] [Abstract][Full Text] [Related]
18. Combined IDH1 mutation and MGMT methylation status on long-term survival of patients with cerebral low-grade glioma.
Tanaka K; Sasayama T; Mizukawa K; Takata K; Sulaiman NS; Nishihara M; Kohta M; Sasaki R; Hirose T; Itoh T; Kohmura E
Clin Neurol Neurosurg; 2015 Nov; 138():37-44. PubMed ID: 26276726
[TBL] [Abstract][Full Text] [Related]
19. Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma.
Raghunathan A; Olar A; Vogel H; Parker JR; Coventry SC; Debski R; Albarracin CT; Aldape KD; Cahill DP; Powell SZ; Fuller GN
Ann Diagn Pathol; 2012 Aug; 16(4):255-9. PubMed ID: 22445362
[TBL] [Abstract][Full Text] [Related]
20. The evolving genomic landscape of recurrent gliomas.
Ampie L; Kusne Y; Sanai N
World Neurosurg; 2015 May; 83(5):722-3. PubMed ID: 25765925
[No Abstract] [Full Text] [Related]
[Next] [New Search]